The United States Food and Drug Administration has approved Rasonque, known generically as daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic treatment or cannot receive multi-drug treatment.

For a cancer that is often diagnosed after it has spread, the decision offers a new option where choices have long been limited. In a 500-patient trial cited by the FDA, people treated with Rasonque had a median overall survival of 13.2 months, compared with 6.7 months for those treated with standard chemotherapy.

That result is important. It is not a cure.

And it does not mean every person prescribed the medicine will live an additional 6.5 months. Median survival is the point at which half the people in a study are alive and half have died. Individual outcomes vary according to the biology of the cancer, previous treatments, overall health and whether side effects can be managed.

The approval may still mark a significant moment for patients with metastatic pancreatic cancer, a disease with one of the highest death rates among major cancers. Its real-world impact, however, will depend on what happens after approval: publication of full trial evidence, the medicine’s price, national regulatory decisions, and whether patients can reach specialised cancer care.

A new treatment option in a difficult disease

Rasonque is a tablet taken once daily. It is designed to inhibit multiple forms of RAS, a group of proteins involved in signalling pathways that can help cancer cells grow and survive.

The FDA said RAS is a key driver of tumour growth in most people with pancreatic adenocarcinoma. This form of pancreatic cancer begins in cells lining the pancreatic ducts and accounts for about 90% to 95% of pancreatic cancer cases, according to the US National Cancer Institute.

The FDA approval is limited to metastatic disease, meaning the cancer has spread beyond the pancreas to other organs or tissues. It is for adults who have received at least one earlier systemic therapy, treatment that circulates through the body, such as chemotherapy, or who are not candidates for combination systemic treatment.

The agency said its decision was based on a randomised, open-label, multicentre clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. In an open-label trial, both patients and clinicians know which treatment is being given.

The FDA granted the drug Breakthrough Therapy and Orphan Drug designations, along with Priority Review. It also reviewed the application through its National Priority Voucher pilot programme, which is intended to speed review of therapies considered important to public health.

These regulatory designations can shorten review timelines. They do not remove the need for evidence on safety and effectiveness.

Why pancreatic cancer remains so hard to treat

Pancreatic cancer is not among the most common cancers globally, but it causes a disproportionate number of cancer deaths. The International Agency for Research on Cancer estimated that pancreatic cancer caused more than 466,000 deaths worldwide in 2022.

Its lethality is closely tied to late diagnosis.

The pancreas sits deep in the abdomen, behind the stomach. Early pancreatic cancer can cause no symptoms, or symptoms that are easily mistaken for less serious conditions. Abdominal or back pain, loss of appetite, unexplained weight loss, fatigue, jaundice and changes in bowel habits may occur only after the disease has progressed.

By then, surgery — the only treatment with curative intent for some patients — may no longer be possible.

For people with metastatic disease (spreading), treatment usually aims to slow tumour growth, extend life and control symptoms. Chemotherapy remains central to care. But not every patient is well enough to receive intensive combinations of drugs, and cancers can become resistant to treatment.

This is why a new treatment option can matter even when it is not curative. Patients and doctors need choices, particularly after a first treatment stops working or causes unacceptable side effects.

What the trial result means and what it does not

The survival difference reported by the FDA is striking: median overall survival of 13.2 months with Rasonque, compared with 6.7 months with standard chemotherapy.

Overall survival is a widely used measure in cancer trials because it records how long patients live after entering a study. It is meaningful to patients and families because it measures an outcome that matters directly.

The FDA listed rash, diarrhoea, stomatitis — inflammation of the lining of the mouth — nausea, fatigue, vomiting, abdominal pain, oedema, reduced appetite and haemorrhage among the medicine’s most common side effects.

Patients considering the treatment should discuss its likely benefits, risks, previous treatments and monitoring requirements with their oncology team. Anyone taking cancer treatment who develops severe or worsening symptoms should contact their treating team promptly.

Treatment is more than a medicine

The approval is a US regulatory decision. It does not mean Rasonque is immediately available in Malaysia, or in any other country.

Before a medicine can be routinely used elsewhere, national regulators must assess it. Health systems and insurers then face further decisions: whether to fund it, for which patients, and at what price. In many countries, a medicine may be registered but remain out of reach because patients must pay privately.

This matters especially in pancreatic cancer, where care is complex and time-sensitive.

Patients may need imaging, biopsy procedures, pathology services, regular blood tests, oncology consultations, treatment monitoring, nutritional support and palliative care. Palliative care focuses on relief from pain, digestive problems, fatigue and other symptoms; it can be provided alongside active cancer treatment.

A test for health systems

The FDA’s early decision shows that regulators can act quickly when a serious disease has few effective treatment options. The agency said it approved Rasonque 6.5 months before the deadline set under user-fee legislation.

But regulatory speed is only one part of the public-interest test. Health systems must not allow a gap to open between scientific progress and patient access.

For patients with metastatic pancreatic cancer, time is measured differently. Delayed scans, unaffordable treatment, absent specialist services and fragmented follow-up are not administrative failures. They can shape whether someone receives care at all.

Rasonque may offer a meaningful new treatment choice for some patients. Whether it changes outcomes beyond clinical trials will depend on whether health systems make that choice reachable, not only for people with the means to pay, but for every patient who may benefit.